The AMDCC is an interdisciplinary consortium designed to develop new animal models that closely mimic the human complication so diabetes for the purpose of studying disease pathogenesis, prevention and treatment. The consortium consists of thirteen "pathobiology sites" that study complications such as diabetic nephropathy, uropathy, neuropathy, cardiomyopathy and vascular disease.

Additional goals of the AMDCC are to define criteria to validate each diabetic complications for its similarity to the human disease, test the role of candidate genes that emerge from human genetic studies, and facilitate the exchange of models, tissues, reagents, and expertise between members of the consortium and the greater scientific community.

To ensure that all models generated by the AMDCC are phenotyped for a full duration of diabetes and across all relevant complications, the consortium has formed a close partnership with the Jackson Laboratories and the NIDDK-funded Mouse Metabolic Phenotyping Centers.

Programme of NIH-JDRF Consensus meeting

The National Institute of Diabetes and Digestive and Kidney Diseases has partnered with the Juvenile Diabetes Research Foundation to support a meeting of scientists to explore the feasibility of establishing a set of guidelines to define diabetic peripheral neuropathy in experimental rodent models. These guidelines may include assessments of behavior and electrophysiology with a variety of biochemical, molecular and anatomical measures. The meeting will occur September 3-4 in Orvieto, Italy. The scientists plan to publish a consensus document emanating from the meeting in the Journal of the Peripheral Nervous System.



Click here for Tutorials and Frequently Asked Questions (FAQ)

	AMDCC Presentations Available The presentations for the semi-annual meetings are now available to the public. These include the invited speakers when available. All presentations are in PDF format to minimize spacre requirements. Just go to About AMDCC => Presentations or click here.

This site is best viewed with Netscape Navigator 6+ and Microsoft Internet Explorer 5.5+